Home › Compare › RVNC vs FCPT

RVNC vs FCPT: Dividend Comparison 2026

RVNC yields 54.79% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVNC wins by $454.0K in total portfolio value
10 years
RVNC
RVNC
● Live price
54.79%
Share price
$3.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503.1K
Annual income
$109,600.15
Full RVNC calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — RVNC vs FCPT

📍 RVNC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVNCFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVNC + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RVNC pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVNC
Annual income on $10K today (after 15% tax)
$4,657.53/yr
After 10yr DRIP, annual income (after tax)
$93,160.13/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, RVNC beats the other by $88,251.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVNC + FCPT for your $10,000?

RVNC: 50%FCPT: 50%
100% FCPT50/50100% RVNC
Portfolio after 10yr
$276.1K
Annual income
$57,687.71/yr
Blended yield
20.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RVNC right now

RVNC
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$20.78
+469.3% upside vs current
Range: $6.66 — $37.00
Altman Z
-6.3
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVNC buys
0
FCPT buys
0
No recent congressional trades found for RVNC or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVNCFCPT
Forward yield54.79% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$503.1K ✓$49.1K
Annual income after 10y$109,600.15 ✓$5,775.28
Total dividends collected$409.6K ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$20.78$27.00 ✓

Year-by-year: RVNC vs FCPT ($10,000, DRIP)

YearRVNC PortfolioRVNC Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$16,179$5,479.45$11,401$700.92+$4.8K → RVNC
2$25,597$8,285.47$13,064$864.84+$12.5K → RVNC
3$39,640$12,250.87$15,051$1,072.48+$24.6K → RVNC
4$60,146$17,730.52$17,442$1,337.22+$42.7K → RVNC
5$89,498$25,142.31$20,340$1,677.08+$69.2K → RVNC
6$130,728$34,964.84$23,880$2,116.57+$106.8K → RVNC
7$187,610$47,731.17$28,241$2,689.36+$159.4K → RVNC
8$264,761$64,018.61$33,660$3,442.07+$231.1K → RVNC
9$367,729$84,434.73$40,456$4,439.95+$327.3K → RVNC
10$503,070$109,600.15$49,063$5,775.28+$454.0K → RVNC

RVNC vs FCPT: Complete Analysis 2026

RVNC — Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Full RVNC Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this RVNC vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVNC vs SCHDRVNC vs JEPIRVNC vs ORVNC vs KORVNC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.